Manual of Lipidology

2. Auflage 2026
ISBN: 978-93-7202-062-5
Verlag: Jaypee Brothers Medical Publishers Pvt Ltd

Buch, Englisch, 346 Seiten, Format (B × H): 159 mm x 241 mm, Gewicht: 550 g

The book provides comprehensive coverage of basic lipid metabolism, lipoprotein biology, and the genetics of dyslipidemia, along with a detailed discussion on international lipid guidelines.

It offers practical guidance on statins, nonstatin therapies, PCSK9 inhibitors, triglyceride-lowering agents, HDL-targeted therapies, and lipoprotein apheresis.

The book also includes updated discussions on apolipoproteins, lipoprotein(a), HDL, and cardiovascular risk, along with dedicated chapters addressing statin intolerance, statin diabetogenicity, diabetic dyslipidemia, and MASLD. Special emphasis has been given to lipid management in specific populations, including pregnancy.

By integrating recent clinical trial evidence, evolving therapeutic strategies, and guideline-based recommendations, the Manual of Lipidology serves as a reliable companion for clinicians involved in cardiovascular risk reduction.

Autoren/Hrsg.

Ghosh, Sujoy

Saboo, Banshi

Inhaltsverzeichnis

Section 1: Basic Lipidology

1. Human Lipoprotein Metabolism: An Overview

2. Lipoproteins: Mechanisms for Atherosclerosis

3. Apolipoprotein B and Cardiovascular Disease

4. Lipoprotein(a): An Update

5. Monogenic Lipoprotein Disorders: From Phenotype to Genotype

Section 2: Clinical Lipidology

6. Dietary Fats and Cardiovascular Disease

7. Dyslipidemia: Relationship with Insulin Resistance, Fatty Liver, and Subclinical Atherosclerosis

8. Risk Assessment of Different Lipid Markers: Clinical Appraisal and Goal of Therapy

9. Rethinking “Good” Cholesterol: Understanding the Role of High-density Lipoprotein

10.Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk

11. Non-HDL is a Better Marker than LDL for Prediction of ASCVD Risk

12. Approach to the Patient with Lipid Disorders

13. Laboratory Assessment of Lipoproteins: Principles and Pitfalls

14. Statins Diabetogenicity: Are All Same?

Section 3: Therapeutic Lipidology

15. The Effects of Diet and Exercise in Hyperlipidemia

16. Metabolic Dysfunction-associated Steatotic Liver Disease: Lipid Disease of Liver and Effect of Lipid-lowering Drugs

17. Beyond Statins: Who and When to Prescribe?

18. Role of Triglyceride Lowering Drugs on Cardiovascular Outcomes: Focus on Omega-3 Fatty Acid

19. HDL-targeting Therapies: Progress and Future

20. Statin Intolerance: Impact on Statin Therapy—Assessment and Management

21. Diabetic Dyslipidemia: Current Concepts and Guidelines

22. Comparative Analysis of Major Cholesterol Guidelines

23. International Lipid Guidelines: Implications for Our Indian Patients—A Cardiologist’s Viewpoint

24. Lipoprotein Apheresis

25. Evolving Targets of Therapies: PCSK9 and Beyond

Section 4: Dyslipidemia in Special Population

26. Management of Dyslipidemia in Chronic Kidney Disease

27. Dyslipidemia in Children and Adolescents: Screening, Diagnosis, and Management

28. Dyslipidemia in Pregnancy

29. Drug Treatment of Dyslipidemia in Older Adults

30. Dyslipidemia in Human Immunodeficiency Virus

Index

Über Autor(innen)

Sujoy Ghosh DM FRCP (London, Glasgow, Edinburgh) FACE FICP

Professor, Department of Endocrinology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India

Banshi Saboo MD PhD MNAMS (Diabetes) FRCP(UK) FACE

Director and Chief Diabetologist, Department of Diabetes, Diabetes Care and Hormone Clinic, Ahmedabad, Gujarat, India